Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

SML1916

Sigma-Aldrich

Marizomib

≥95% (HPLC), (Salinospora tropica)

Sinonimo/i:

(1R,4R,5S)-4-(2-Chloroethyl)-1-[(S)-(1S)-2-cyclohexen-1-ylhydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, NPI-0052, Salinosporamide A

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

100 μG
163,00 €

163,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
100 μG
163,00 €

About This Item

Formula empirica (notazione di Hill):
C15H20ClNO4
Numero CAS:
437742-34-2
Peso molecolare:
313.78
Codice UNSPSC:
12352200
NACRES:
NA.77

163,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk

Livello qualitativo

100

Origine biologica

(Salinospora tropica)

Saggio

≥95% (HPLC)

Stato

powder

Condizioni di stoccaggio

desiccated

Colore

white to beige

Condizioni di spedizione

wet ice

Temperatura di conservazione

−20°C

Stringa SMILE

ClCC[C@@H]1[C@@]2(OC(=O)[C@@]2(NC1=O)[C@@H](O)[C@H]3CCCC=C3)C

InChI

1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
NGWSFRIPKNWYAO-SHTIJGAHSA-N

Applicazioni

Marizomib has been used as a proteasome inhibitor:
  • to study its effects on glioblastoma cell lines[1]
  • to analyze its effects on the aging of killifish brain[2]
  • to test its effect on protein kinase B (PKB/AKT) levels in multiple myeloma cells[3]

Azioni biochim/fisiol

Marizomib a natural product is a marine-derived β-lactone-γ-lactam. It shows therapeutic effects against hematologic and solid tumor malignancies.[4]. It is involved in the activation of caspase-3,-8, and -9, increases the reactive oxygen species (ROS) and promotes apoptosis. Marizomib can cross the blood-brain barrier and might have the potential to treat primary brain tumors. It possesses anti-tumor properties.[5]
Marizomib is a second generation proteasome inhibitor with anti-cancer activity.
Marizomib is a second generation proteasome inhibitor with anti-cancer activity. Marizomib binds irreversibly and potently inhibits all three 20S proteasome subunits.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000055025

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Nancy Levin et al.
British journal of haematology, 174(5), 711-720 (2016-05-11)
Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly observed. All clinical stage PIs effectively inhibit chymotrypsin-like (CT-L) activity; one possible mechanism of resistance is compensatory hyperactivation of caspase-like (C-L) and trypsin-like (T-L) subunits, in
Kaijun Di et al.
Neuro-oncology, 18(6), 840-848 (2015-12-19)
The proteasome plays a vital role in the physiology of glioblastoma (GBM), and proteasome inhibition can be used as a strategy for treating GBM. Marizomib is a second-generation, irreversible proteasome inhibitor with a more lipophilic structure that suggests the potential
A M Rajan et al.
Blood cancer journal, 6(7), e451-e451 (2016-07-30)
The treatment of multiple myeloma (MM) is rapidly evolving. In the United States, four drugs (panobinostat, ixazomib, daratumumab and elotuzumab) were approved for the treatment of MM in 2015. As a result of improved diagnosis and therapy, there has been
B C Potts et al.
Current cancer drug targets, 11(3), 254-284 (2011-01-21)
The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration approved the first-in-class proteasome inhibitor bortezomib (Velcade) for the treatment of relapsed/refractory multiple myeloma (MM) and mantle cell
Erika Kelmer Sacramento et al.
Molecular systems biology, 16(6), e9596-e9596 (2020-06-20)
A progressive loss of protein homeostasis is characteristic of aging and a driver of neurodegeneration. To investigate this process quantitatively, we characterized proteome dynamics during brain aging in the short-lived vertebrate Nothobranchius furzeri combining transcriptomics and proteomics. We detected a
Visualizza tutti i documenti correlati

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.